Please login to the form below
PD-L1 inhibitors
This page shows the latest PD-L1 inhibitors news and features for those working in and with pharma, biotech and healthcare.
Gilead makes a play for novel cancer drug with Tizona deal
anti-PD-1/L1 therapies and deepen responses in tumours that are sensitive to these treatments. ... Gilead, however, is looking past PD-1/L1 inhibitors to the next class of transformative treatments, with its play for Tizona just the latest in a string of
Latest news
-
Tecentriq misses the mark in advanced ovarian cancer
Tecentriq is part of a new class of immunotherapy treatments, also known as PD-1/L1 inhibitors, that have transformed the market over the last few years. ... The FDA approval for Imfinzi makes AZ’s drug the first PD-1/PD-L1 inhibitor to challenge
-
Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer
PD-L1 inhibitor – this time stumbling in head and neck cancer. ... 1/PD-L1 inhibitors spilling across a number of cancer types and ramping up the competition.
-
AstraZeneca’s Imfinzi fails first-line bladder cancer test
PD-L1 inhibitor Imfinzi (durvalumab) – given on its own and in combination with experimental CTLA4 inhibitor tremelimumab – wasn’t able to improve overall survival in patients with advanced (stage IV) bladder ... In the trial, Imfinzi monotherapy
-
Immutep spikes on trial of its LAG-3 drug with Keytruda
The PD-1/PD-L1 checkpoint inhibitors that hit the market in 2015 have already transformed the standard of care for some cancers, but there is still a sizeable patient population ... so “the results showing an almost 50% [response] across all patients
-
Innate Pharma and AstraZeneca take monalizumab into phase 3
AZ has vested interested in Innate’s candidate because of data which shows that it can improve the effectiveness of PD-1/PD-L1 inhibitors like AZ’s own Imfinzi (durvalumab).
Tecentriq misses the mark in advanced ovarian cancer
Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer
AstraZeneca’s Imfinzi fails first-line bladder cancer test
Immutep spikes on trial of its LAG-3 drug with Keytruda
Innate Pharma and AstraZeneca take monalizumab into phase 3
More from news
Approximately 1 fully matching, plus 43 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing
-
The good, the bad and the ugly
Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response,” says Xuan.
-
European venture funding for the life science sector
is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture
-
Medius Deal Watch table for March 2015
170. Checkpoint Therapeutics / TG. Licence and collaboration. Human anti-PD-L1 and anti-GITR antibody preclinical programmes for haematological cancers. ... CAR-T and checkpoint inhibitors PD-1 and PD-L1. 110. Transtech / Calithera.
-
Deal Watch table for November 2014
PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).
Immuno-oncology in 2019: the rapid evolution continues
The good, the bad and the ugly
European venture funding for the life science sector
Medius Deal Watch table for March 2015
Deal Watch table for November 2014
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Understanding the ‘real world’ starts and ends with the patient
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Sanofi raises profit forecast following positive Q2 results
- Biogen/Eisai push for second approval in Alzheimer’s disease
- Reducing primary care antibiotic use may not be enough to counter antimicrobial resistance
- SoftBank buys $5bn stake in Roche
- Live Webinar: Making Wearable Technology Scalable and Adoptable
- Live Webinar: Transforming the Future of Health & Aging from a Global Health & Social Impact Approach
- Investors respond positively to “strong” Eli Lilly results
- Amanda Pritchard becomes NHS England’s first female chief executive
- Biogen/Eisai push for second approval in Alzheimer’s disease
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Resilience acquires bluebird bio’s manufacturing facility as part of cell therapy alliance
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Ask the writers: Transitioning from academia to medical writing
- Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
- Strategic launch planning: familiar framework, new mindset
- By James Aird...
- Guide
- How to embrace behavioural science principles in healthcare MR...
